To translate, or not to translate: Viral and host mRNA regulation by interferon-stimulated genes

Trends in Cell Biology

Volumn 25, Issue 6, 2015, Pages 320-329

  Li, Melody M H ^a   MacDonald, Margaret R ^a   Rice, Charles M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

MicroRNA function; MicroRNA processing; Translational regulation

Indexed keywords

INTERFERON; MESSENGER RNA; MICRORNA; VIRUS RNA;

ADAR1 GENE; CELL GRANULE; GENE; GENE LOCATION; GENE PRODUCT; GENE SILENCING; HOST; HUMAN; IFIT1 GENE; INTERFERON STIMULATED GENE; ISG15 GENE; MOV10 GENE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SLFN11 GENE; TRANSLATION REGULATION; UPREGULATION; VIROGENESIS; VIRUS REPLICATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM;

ANIMALS; GENE EXPRESSION REGULATION; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERONS; MICRORNAS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84929517045     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2015.02.001     Document Type: Review

References (131)

1. Schneider W.M., et al. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 2014, 32:513-545.
2. Schoggins J.W., et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
3. Jackson R.J., et al. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat. Rev. Mol. Cell Biol. 2010, 11:113-127.
4. Ryman K.D., et al. Sindbis virus translation is inhibited by a PKR/RNase L-independent effector induced by alpha/beta interferon priming of dendritic cells. J. Virol. 2005, 79:1487-1499.
5. Wang N., et al. Viral induction of the zinc finger antiviral protein is IRF3-dependent but NF-kappaB-independent. J. Biol. Chem. 2010, 285:6080-6090.
6. Kerns J.A., et al. Positive selection and increased antiviral activity associated with the PARP-containing isoform of human zinc-finger antiviral protein. PLoS Genet. 2008, 4. Published online January 25, 2008. http://dx.doi.org/10.1371/journal.pgen.0040021.
7. Hayakawa S., et al. ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses. Nat. Immunol. 2011, 12:37-44.
8. Mao R., et al. Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog. 2013, 9. Published online July 11, 2013. http://dx.doi.org/10.1371/journal.ppat.1003494.
9. Seo G.J., et al. Reciprocal inhibition between intracellular antiviral signaling and the RNAi machinery in mammalian cells. Cell Host Microbe 2013, 14:435-445.
10. Gao G., et al. Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science 2002, 297:1703-1706.
11. Bick M.J., et al. Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J. Virol. 2003, 77:11555-11562.
12. Muller S., et al. Inhibition of filovirus replication by the zinc finger antiviral protein. J. Virol. 2007, 81:2391-2400.
13. Wang X., et al. Zinc-finger antiviral protein inhibits XMRV infection. PLoS ONE 2012, 7. Published online June 15, 2012. http://dx.doi.org/10.1371/journal.pone.0039159.
14. Zhu Y., et al. Zinc-finger antiviral protein inhibits HIV-1 infection by selectively targeting multiply spliced viral mRNAs for degradation. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:15834-15839.
15. Guo X., et al. The zinc finger antiviral protein directly binds to specific viral mRNAs through the CCCH zinc finger motifs. J. Virol. 2004, 78:12781-12787.
16. Chen G., et al. p72 DEAD box RNA helicase is required for optimal function of the zinc-finger antiviral protein. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4352-4357.
17. Guo X., et al. The zinc-finger antiviral protein recruits the RNA processing exosome to degrade the target mRNA. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:151-156.
18. Todorova T., et al. PARP13 regulates cellular mRNA post-transcriptionally and functions as a pro-apoptotic factor by destabilizing TRAILR4 transcript. Nat. Commun. 2014, 5. Published online November 10, 2014. http://dx.doi.org/10.1038/ncomms6362.
19. Zhu Y., et al. Translational repression precedes and is required for ZAP-mediated mRNA decay. EMBO J. 2012, 31:4236-4246.
20. Atasheva S., et al. New PARP gene with an anti-alphavirus function. J. Virol. 2012, 86:8147-8160.
21. Atasheva S., et al. Interferon-stimulated poly(ADP-Ribose) polymerases are potent inhibitors of cellular translation and virus replication. J. Virol. 2014, 88:2116-2130.
22. Welsby I., et al. PARP12, an interferon-stimulated gene involved in the control of protein translation and inflammation. J. Biol. Chem. 2014, 289:26642-26657.
23. Guo J., et al. Induction of the human protein P56 by interferon, double-stranded RNA, or virus infection. Virology 2000, 267:209-219.
24. Terenzi F., et al. Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56. J. Biol. Chem. 2006, 281:34064-34071.
25. Diamond M.S., Farzan M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat. Rev. Immunol. 2013, 13:46-57.
26. Daffis S., et al. 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 2010, 468:452-456.
27. Habjan M., et al. Sequestration by IFIT1 impairs translation of 2'O-unmethylated capped RNA. PLoS Pathog. 2013, 9. Published online October 3, 2013. http://dx.doi.org/10.1371/journal.ppat.1003663.
28. Kimura T., et al. Ifit1 inhibits Japanese encephalitis virus replication through binding to 5' capped 2'-O unmethylated RNA. J. Virol. 2013, 87:9997-10003.
29. Szretter K.J., et al. 2'-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo. PLoS Pathog. 2012, 8. Published online May 10, 2012. http://dx.doi.org/10.1371/journal.ppat.1002698.
30. Zust R., et al. Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 2011, 12:137-143.
31. Abbas Y.M., et al. Structural basis for viral 5'-PPP-RNA recognition by human IFIT proteins. Nature 2013, 494:60-64.
32. Pichlmair A., et al. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat. Immunol. 2011, 12:624-630.
33. Hyde J.L., et al. A viral RNA structural element alters host recognition of nonself RNA. Science 2014, 343:783-787.
34. Guo J., et al. A new pathway of translational regulation mediated by eukaryotic initiation factor 3. EMBO J. 2000, 19:6891-6899.
35. Hui D.J., et al. Viral stress-inducible protein p56 inhibits translation by blocking the interaction of eIF3 with the ternary complex eIF2.GTP, Met-tRNAi. J. Biol. Chem. 2003, 278:39477-39482.
36. Wang C., et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J. Virol. 2003, 77:3898-3912.
37. Grantham P., Perrin P. AIDS virus and HTLV-I differ in codon choices. Nature 1986, 319:727-728.
38. Meintjes P.L., Rodrigo A.G. Evolution of relative synonymous codon usage in human immunodeficiency virus type-1. J. Bioinform. Comput. Biol. 2005, 3:157-168.
39. van Weringh A., et al. HIV-1 modulates the tRNA pool to improve translation efficiency. Mol. Biol. Evol. 2011, 28:1827-1834.
40. Li M., et al. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature 2012, 491:125-128.
41. Geserick P., et al. Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motif. Int. Immunol. 2004, 16:1535-1548.
42. Schwarz D.A., et al. Schlafen, a new family of growth regulatory genes that affect thymocyte development. Immunity 1998, 9:657-668.
43. Sohn W.J., et al. Novel transcriptional regulation of the schlafen-2 gene in macrophages in response to TLR-triggered stimulation. Mol. Immunol. 2007, 44:3273-3282.
44. Morales D.J., Lenschow D.J. The antiviral activities of ISG15. J. Mol. Biol. 2013, 425:4995-5008.
45. Gradi A., et al. Proteolysis of human eukaryotic translation initiation factor eIF4GII, but not eIF4GI, coincides with the shutoff of host protein synthesis after poliovirus infection. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:11089-11094.
46. Rahnefeld A., et al. Ubiquitin-like protein ISG15 in host defense against heart failure in a mouse model of virus-induced cardiomyopathy. Circulation 2014, 130:1589-1600. http://dx.doi/10.1161/CIRCULATIONAHA.114.009847. Epub 2014 Aug 27.
47. Anderson P., Kedersha N. Stress granules: the Tao of RNA triage. Trends Biochem. Sci. 2008, 33:141-150.
48. Buchan J.R., Parker R. Eukaryotic stress granules: the ins and outs of translation. Mol. Cell 2009, 36:932-941.
49. Onomoto K., et al. Antiviral innate immunity and stress granule responses. Trends Immunol. 2014, 35:420-428.
50. Liu J., et al. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat. Cell Biol. 2005, 7:719-723.
51. Pillai R.S., et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005, 309:1573-1576.
52. Sen G.L., Blau H.M. Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies. Nat. Cell Biol. 2005, 7:633-636.
53. Yang J.S., Lai E.C. Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. Mol. Cell 2011, 43:892-903.
54. Leung A.K., et al. Poly(ADP-ribose) regulates stress responses and microRNA activity in the cytoplasm. Mol. Cell 2011, 42:489-499.
55. Kleine H., et al. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol. Cell 2008, 32:57-69.
56. Fairman-Williams M.E., et al. SF1 and SF2 helicases: family matters. Curr. Opin. Struct. Biol. 2010, 20:313-324.
57. Arjan-Odedra S., et al. Endogenous MOV10 inhibits the retrotransposition of endogenous retroelements but not the replication of exogenous retroviruses. Retrovirology 2012, 9:53.
58. Burdick R., et al. P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages. J. Virol. 2010, 84:10241-10253.
59. Haussecker D., et al. Capped small RNAs and MOV10 in human hepatitis delta virus replication. Nat. Struct. Mol. Biol. 2008, 15:714-721.
60. Li X., et al. The MOV10 helicase inhibits LINE-1 mobility. J. Biol. Chem. 2013, 288:21148-21160.
61. Lu C., et al. Moloney leukemia virus type 10 inhibits reverse transcription and retrotransposition of intracisternal a particles. J. Virol. 2012, 86:10517-10523.
62. Wang X., et al. Moloney leukemia virus 10 (MOV10) protein inhibits retrovirus replication. J. Biol. Chem. 2010, 285:14346-14355.
63. Meister G., et al. Identification of novel argonaute-associated proteins. Curr. Biol. 2005, 15:2149-2155.
64. Banerjee S., et al. A coordinated local translational control point at the synapse involving relief from silencing and MOV10 degradation. Neuron 2009, 64:871-884.
65. Chendrimada T.P., et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005, 436:740-744.
66. Gregory R.I., et al. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005, 123:631-640.
67. Chendrimada T.P., et al. MicroRNA silencing through RISC recruitment of eIF6. Nature 2007, 447:823-828.
68. Liu C., et al. APOBEC3G inhibits microRNA-mediated repression of translation by interfering with the interaction between Argonaute-2 and MOV10. J. Biol. Chem. 2012, 287:29373-29383.
69. Wichroski M.J., et al. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog. 2006, 2. Published online May 12, 2006. http://dx.doi.org/10.1371/journal.ppat.0020041.
70. George C.X., et al. Adenosine deaminases acting on RNA, RNA editing, and interferon action. J. Interferon Cytokine Res. 2011, 31:99-117.
71. Athanasiadis A., et al. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol. 2004, 2:e391. http://dx.doi.org/10.1371/journal.pbio.0020391. Epub 2004 Nov 9.
72. Kim D.D., et al. Widespread RNA editing of embedded alu elements in the human transcriptome. Genome Res. 2004, 14:1719-1725.
73. Levanon E.Y., et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat. Biotechnol. 2004, 22:1001-1005.
74. Ramaswami G., et al. Accurate identification of human Alu and non-Alu RNA editing sites. Nat. Methods 2012, 9:579-581.
75. Sakurai M., et al. Inosine cyanoethylation identifies A-to-I RNA editing sites in the human transcriptome. Nat. Chem. Biol. 2010, 6:733-740.
76. Wulff B.E., et al. Elucidating the inosinome: global approaches to adenosine-to-inosine RNA editing. Nat. Rev. Genet. 2011, 12:81-85.
77. Baczko K., et al. Clonal expansion of hypermutated measles virus in a SSPE brain. Virology 1993, 197:188-195.
78. Carpenter J.A., et al. Evidence for ADAR-induced hypermutation of the Drosophila sigma virus (Rhabdoviridae). BMC Genet. 2009, 10. Published online November 26, 2009. http://dx.doi.org/10.1186/1471-2156-10-75.
79. Cattaneo R., et al. Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell 1988, 55:255-265.
80. Ko N.L., et al. Hyperediting of human T-cell leukemia virus type 2 and simian T-cell leukemia virus type 3 by the dsRNA adenosine deaminase ADAR-1. J. Gen. Virol. 2012, 93:2646-2651.
81. Kumar M., Carmichael G.G. Nuclear antisense RNA induces extensive adenosine modifications and nuclear retention of target transcripts. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:3542-3547.
82. Liu Y., et al. Circulating type 1 vaccine-derived poliovirus may evolve under the pressure of adenosine deaminases acting on RNA. J. Matern. Fetal Neonatal Med. 2014, Published online November 14, 2014. http://dx.doi.org/10.3109/14767058.2014.979147.
83. Luo G.X., et al. A specific base transition occurs on replicating hepatitis delta virus RNA. J. Virol. 1990, 64:1021-1027.
84. Rima B.K., et al. Stability of the parainfluenza virus 5 genome revealed by deep sequencing of strains isolated from different hosts and following passage in cell culture. J. Virol. 2014, 88:3826-3836.
85. Suspene R., et al. Double-stranded RNA adenosine deaminase ADAR-1-induced hypermutated genomes among inactivated seasonal influenza and live attenuated measles virus vaccines. J. Virol. 2011, 85:2458-2462.
86. Taylor D.R., et al. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J. Virol. 2005, 79:6291-6298.
87. Tenoever B.R., et al. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 2007, 315:1274-1278.
88. Zahn R.C., et al. A-to-G hypermutation in the genome of lymphocytic choriomeningitis virus. J. Virol. 2007, 81:457-464.
89. Desterro J.M., et al. Dynamic association of RNA-editing enzymes with the nucleolus. J. Cell Sci. 2003, 116:1805-1818.
90. Eckmann C.R., et al. The human but not the Xenopus RNA-editing enzyme ADAR1 has an atypical nuclear localization signal and displays the characteristics of a shuttling protein. Mol. Biol. Cell 2001, 12:1911-1924.
91. Strehblow A., et al. Nucleocytoplasmic distribution of human RNA-editing enzyme ADAR1 is modulated by double-stranded RNA-binding domains, a leucine-rich export signal, and a putative dimerization domain. Mol. Biol. Cell 2002, 13:3822-3835.
92. Fritz J., et al. RNA-regulated interaction of transportin-1 and exportin-5 with the double-stranded RNA-binding domain regulates nucleocytoplasmic shuttling of ADAR1. Mol. Cell Biol. 2009, 29:1487-1497.
93. Ota H., et al. ADAR1 forms a complex with dicer to promote microRNA processing and RNA-induced gene silencing. Cell 2013, 153:575-589.
94. Ng S.K., et al. Proteins that contain a functional Z-DNA-binding domain localize to cytoplasmic stress granules. Nucleic Acids Res. 2013, 41:9786-9799.
95. Weissbach R., Scadden A.D. Tudor-SN and ADAR1 are components of cytoplasmic stress granules. RNA 2012, 18:462-471.
96. Kawahara Y., et al. Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science 2007, 315:1137-1140.
97. Yang W., et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat. Struct. Mol. Biol. 2006, 13:13-21.
98. Nachmani D., et al. MicroRNA editing facilitates immune elimination of HCMV infected cells. PLoS Pathog. 2014, 10. Published online February 27, 2014. http://dx.doi.org/10.1371/journal.ppat.1003963.
99. Joklik W.K., Merigan T.C. Concerning the mechanism of action of interferon. Proc. Natl. Acad. Sci. U.S.A. 1966, 56:558-565.
100. Metz D.H., Esteban M. Interferon inhibits viral protein synthesis in L cells infected with vaccinia virus. Nature 1972, 238:385-388.
101. Content J., et al. Blocks in elongation and initiation of protein synthesis induced by interferon treatment in mouse L cells. Eur. J. Biochem. 1975, 54:1-10.
102. Kerr I.M., et al. Increased sensitivity of cell-free protein synthesis to double-stranded RNA after interferon treatment. Nature 1974, 250:57-59.
103. Ball L.A., White C.N. Oligonucleotide inhibitor of protein synthesis made in extracts of interferon-treated chick embryo cells: comparison with the mouse low molecular weight inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:1167-1171.
104. Cooper J.A., Farrell P.J. Extracts of interferon-treated cells can inhibit reticulocyte lysate protein synthesis. Biochem. Biophys. Res. Commun. 1977, 77:124-131.
105. Hovanessian A.G., et al. Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells. Nature 1977, 268:537-540.
106. Kerr I.M., Brown R.E. pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:256-260.
107. Kerr I.M., et al. Nature of inhibitor of cell-free protein synthesis formed in response to interferon and double-stranded RNA. Nature 1977, 268:540-542.
108. Lebleu B., et al. Interferon, double-stranded RNA, and protein phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 1976, 73:3107-3111.
109. Roberts W.K., et al. Interferon-induced inhibition of protein synthesis in L-cell extracts: an ATP-dependent step in the activation of an inhibitor by double-stranded RNA. Proc. Natl. Acad. Sci. U.S.A. 1976, 73:3136-3140.
110. Roberts W.K., et al. Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis. Nature 1976, 264:477-480.
111. Zilberstein A., et al. Specific phosphorylation in vitro of a protein associated with ribosomes of interferon-treated mouse L cells. FEBS Lett. 1976, 68:119-124.
112. Farrell P.J., et al. Phosphorylation of initiation factor elF-2 and the control of reticulocyte protein synthesis. Cell 1977, 11:187-200.
113. Hovanessian A.G., Kerr I.M. The (2'-5') oligoadenylate (pppA2'-5'A2'-5'A) synthetase and protein kinase(s) from interferon-treated cells. Eur. J. Biochem. 1979, 93:515-526.
114. Kramer G., et al. Specificity of the protein kinase activity associated with the hemin-controlled repressor of rabbit reticulocyte. Proc. Natl. Acad. Sci. U.S.A. 1976, 73:3078-3082.
115. Levin D., London I.M. Regulation of protein synthesis: activation by double-stranded RNA of a protein kinase that phosphorylates eukaryotic initiation factor 2. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:1121-1125.
116. Levin D., et al. Regulation of protein synthesis in reticulocyte lysates: phosphorylation of methionyl-tRNAf binding factor by protein kinase activity of translational inhibitor isolated from hemedeficient lysates. Proc. Natl. Acad. Sci. U.S.A. 1976, 73:3112-3116.
117. Samuel C.E. Mechanism of interferon action: phosphorylation of protein synthesis initiation factor eIF-2 in interferon-treated human cells by a ribosome-associated kinase processing site specificity similar to hemin-regulated rabbit reticulocyte kinase. Proc. Natl. Acad. Sci. U.S.A. 1979, 76:600-604.
118. Williams B.R. Signal integration via PKR. Sci STKE. 2001, Published online July 3, 2001. http://dx.doi.org/10.1126/stke.2001.89.re2.
119. Ratner L., et al. Interferon, double-stranded RNA and RNA degradation. Fractionation of the endonucleaseINT system into two macromolecular components; role of a small molecule in nuclease activation. Biochem. Biophys. Res. Commun. 1978, 81:947-954.
120. Baglioni C., et al. Interferon action may be mediated by activation of a nuclease by pppA2'p5'A2'p5'A. Nature 1978, 273:684-687.
121. Clemens M.J., Williams B.R. Inhibition of cell-free protein synthesis by pppA2'p5'A2'p5'A: a novel oligonucleotide synthesized by interferon-treated L cell extracts. Cell 1978, 13:565-572.
122. Silverman R.H., et al. Control of the ppp(a2'p)nA system in HeLa cells. Effects of interferon and virus infection. Eur. J. Biochem. 1982, 124:131-138.
123. Poirier G.G., et al. Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:3423-3427.
124. Rosado M.M., et al. Beyond DNA repair, the immunological role of PARP-1 and its siblings. Immunology 2013, 139:428-437.
125. Schreiber V., et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J. Biol. Chem. 2002, 277:23028-23036.
126. Virag L., et al. Poly(ADP-ribose) signaling in cell death. Mol. Aspects Med. 2013, 34:1153-1167.
127. Daugherty M.D., et al. Rapid evolution of PARP genes suggests a broad role for ADP-ribosylation in host-virus conflicts. PLoS Genet. 2014, 10. Published online May 29, 2014. http://dx.doi.org/10.1371/journal.pgen.1004403.
128. Dunstan M.S., et al. Structure and mechanism of a canonical poly(ADP-ribose) glycohydrolase. Nat. Commun. 2012, 3. Published online June 6, 2012. http://dx.doi.org/10.1038/ncomms1889.
129. Slade D., et al. The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase. Nature 2011, 477:616-620.
130. Jankevicius G., et al. A family of macrodomain proteins reverses cellular mono-ADP-ribosylation. Nat. Struct. Mol. Biol. 2013, 20:508-514.
131. Rosenthal F., et al. Macrodomain-containing proteins are new mono-ADP-ribosylhydrolases. Nat. Struct. Mol. Biol. 2013, 20:502-507.